Targeting Wnt/β-catenin pathway in hepatocellular carcinoma treatment

World Journal of Gastroenterology

Volumn 22, Issue 2, 2016, Pages 823-832

  Vilchez, Valery ^a   Turcios, Lilia ^a   Marti, Francesc ^a   Gedaly, Roberto ^a  

^a UNIVERSITY OF KENTUCKY   (United States)

Author keywords

Hepatocellular carcinoma; Liver cancer stem cells; Molecular therapy; Wnt catenin pathway

Indexed keywords

7,8 DIHYDRO 2 [4 (TRIFLUOROMETHYL)PHENYL] 5H THIOPYRANO[4,3 D]PYRIMIDIN 4 OL; BETA CATENIN; CHRYSIN; GEMCITABINE; IRINOTECAN; MICRORNA; PACLITAXEL; PYRVINIUM EMBONATE; SORAFENIB; VANTICTUMAB; ANTINEOPLASTIC AGENT; CTNNB1 PROTEIN, HUMAN;

ANTINEOPLASTIC ACTIVITY; CONTROLLED CLINICAL TRIAL (TOPIC); HUMAN; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; MOLECULAR THERAPY; MOLECULARLY TARGETED THERAPY; PROTEIN FUNCTION; REVIEW; STEM CELL; TUMOR GROWTH; UPREGULATION; WNT SIGNALING PATHWAY; ANIMAL; ANTAGONISTS AND INHIBITORS; CARCINOMA, HEPATOCELLULAR; CELL TRANSFORMATION; DRUG EFFECTS; GENETICS; LIVER NEOPLASMS; METABOLISM; PATHOLOGY; TREATMENT OUTCOME;

ANIMALS; ANTINEOPLASTIC AGENTS; BETA CATENIN; CARCINOMA, HEPATOCELLULAR; CELL TRANSFORMATION, NEOPLASTIC; HUMANS; LIVER NEOPLASMS; MOLECULAR TARGETED THERAPY; TREATMENT OUTCOME; WNT SIGNALING PATHWAY;

EID: 84954417122     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v22.i2.823     Document Type: Review

References (76)

1. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet 2003; 362: 1907-1917 [PMID: 14667750 DOI: 10.1016/S0140-6736(03)14964-1]
2. El-Serag HB. Hepatocellular carcinoma. N Engl J Med 2011; 365: 1118-1127 [PMID: 21992124 DOI: 10.1056/NEJMra1001683]
3. Llovet JM, Bruix J. Molecular targeted therapies in hepatocellular carcinoma. Hepatology 2008; 48: 1312-1327 [PMID: 18821591 DOI: 10.1002/hep.22506]
4. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I, Häussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D, Bruix J. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359: 378-390 [PMID: 18650514 DOI: 10.1056/NEJMoa0708857]
5. Kudo M. Current status of molecularly targeted therapy for hepatocellular carcinoma: clinical practice. Int J Clin Oncol 2010; 15: 242-255 [PMID: 20509038 DOI: 10.1007/s10147-010-0089-y]
6. Laurent-Puig P, Zucman-Rossi J. Genetics of hepatocellular tumors. Oncogene 2006; 25: 3778-3786 [PMID: 16799619 DOI: 10.1038/sj.onc.1209547]
7. Nejak-Bowen KN, Monga SP. Beta-catenin signaling, liver regeneration and hepatocellular cancer: sorting the good from the bad. Semin Cancer Biol 2011; 21: 44-58 [PMID: 21182948 DOI: 10.1016/j.semcancer.2010.12.010]
8. Clevers H, Nusse R. Wnt/β-catenin signaling and disease. Cell 2012; 149: 1192-1205 [PMID: 22682243 DOI: 10.1016/j.cell.2012.05.012]
9. Lee HC, Kim M, Wands JR. Wnt/Frizzled signaling in hepatocellular carcinoma. Front Biosci 2006; 11: 1901-1915 [PMID: 16368566]
10. Giles RH, van Es JH, Clevers H. Caught up in a Wnt storm: Wnt signaling in cancer. Biochim Biophys Acta 2003; 1653: 1-24 [PMID: 12781368]
11. Lachenmayer A, Alsinet C, Savic R, Cabellos L, Toffanin S, Hoshida Y, Villanueva A, Minguez B, Newell P, Tsai HW, Barretina J, Thung S, Ward SC, Bruix J, Mazzaferro V, Schwartz M, Friedman SL, Llovet JM. Wnt-pathway activation in two molecular classes of hepatocellular carcinoma and experimental modulation by sorafenib. Clin Cancer Res 2012; 18: 4997-5007 [PMID: 22811581 DOI: 10.1158/1078-0432.CCR-11-2322]
12. Galuppo R, Maynard E, Shah M, Daily MF, Chen C, Spear BT, Gedaly R. Synergistic inhibition of HCC and liver cancer stem cell proliferation by targeting RAS/RAF/MAPK and WNT/β-catenin pathways. Anticancer Res 2014; 34: 1709-1713 [PMID: 24692700]
13. Gedaly R, Galuppo R, Daily MF, Shah M, Maynard E, Chen C, Zhang X, Esser KA, Cohen DA, Evers BM, Jiang J, Spear BT. Targeting the Wnt/β-catenin signaling pathway in liver cancer stem cells and hepatocellular carcinoma cell lines with FH535. PLoS One 2014; 9: e99272 [PMID: 24940873 DOI: 10.1371/journal. pone.0099272]
14. Reya T, Clevers H. Wnt signalling in stem cells and cancer. Nature 2005; 434: 843-850 [PMID: 15829953 DOI: 10.1038/nature03319]
15. Cavard C, Colnot S, Audard V, Benhamouche S, Finzi L, Torre C, Grimber G, Godard C, Terris B, Perret C. Wnt/beta-catenin pathway in hepatocellular carcinoma pathogenesis and liver physiology. Future Oncol 2008; 4: 647-660 [PMID: 18922122 DOI: 10.2217/14796694.4.5.647]
16. Zeng X, Tamai K, Doble B, Li S, Huang H, Habas R, Okamura H, Woodgett J, He X. A dual-kinase mechanism for Wnt co-receptor phosphorylation and activation. Nature 2005; 438: 873-877 [PMID: 16341017 DOI: 10.1038/nature04185]
17. Oishi N, Yamashita T, Kaneko S. Molecular biology of liver cancer stem cells. Liver Cancer 2014; 3: 71-84 [PMID: 24944998 DOI: 10.1159/000343863]
18. Delgado ER, Yang J, So J, Leimgruber S, Kahn M, Ishitani T, Shin D, Mustata Wilson G, Monga SP. Identification and characterization of a novel small-molecule inhibitor of β-catenin signaling. Am J Pathol 2014; 184: 2111-2122 [PMID: 24819961 DOI: 10.1016/j.ajpath.2014.04.002]
19. Liu J, Li G, Liu D, Liu J. FH535 inhibits the proliferation of HepG2 cells via downregulation of the Wnt/β-catenin signaling pathway. Mol Med Rep 2014; 9: 1289-1292 [PMID: 24482011 DOI: 10.3892/mmr.2014.1928]
20. Rubinfeld B, Souza B, Albert I, Müller O, Chamberlain SH, Masiarz FR, Munemitsu S, Polakis P. Association of the APC gene product with beta-catenin. Science 1993; 262: 1731-1734 [PMID: 8259518]
21. Su LK, Vogelstein B, Kinzler KW. Association of the APC tumor suppressor protein with catenins. Science 1993; 262: 1734-1737 [PMID: 8259519]
22. Harada N, Oshima H, Katoh M, Tamai Y, Oshima M, Taketo MM. Hepatocarcinogenesis in mice with beta-catenin and Ha-ras gene mutations. Cancer Res 2004; 64: 48-54 [PMID: 14729607]
23. Breuhahn K, Longerich T, Schirmacher P. Dysregulation of growth factor signaling in human hepatocellular carcinoma. Oncogene 2006; 25: 3787-3800 [PMID: 16799620 DOI: 10.1038/sj.onc.1209556]
24. Salahshor S, Woodgett JR. The links between axin and carcinogenesis. J Clin Pathol 2005; 58: 225-236 [PMID: 15735151 DOI: 10.1136/jcp.2003.009506]
25. Satoh S, Daigo Y, Furukawa Y, Kato T, Miwa N, Nishiwaki T, Kawasoe T, Ishiguro H, Fujita M, Tokino T, Sasaki Y, Imaoka S, Murata M, Shimano T, Yamaoka Y, Nakamura Y. AXIN1 mutations in hepatocellular carcinomas, and growth suppression in cancer cells by virus-mediated transfer of AXIN1. Nat Genet 2000; 24: 245-250 [PMID: 10700176 DOI: 10.1038/73448]
26. Anastas JN, Moon RT. WNT signalling pathways as therapeutic targets in cancer. Nat Rev Cancer 2013; 13: 11-26 [PMID: 23258168 DOI: 10.1038/nrc3419]
27. Cieply B, Zeng G, Proverbs-Singh T, Geller DA, Monga SP. Unique phenotype of hepatocellular cancers with exon-3 mutations in beta-catenin gene. Hepatology 2009; 49: 821-831 [PMID: 19101982 DOI: 10.1002/hep.22695]
28. Wong CM, Fan ST, Ng IO. beta-Catenin mutation and over-expression in hepatocellular carcinoma: clinicopathologic and prognostic significance. Cancer 2001; 92: 136-145 [PMID: 11443619]
29. Inagawa S, Itabashi M, Adachi S, Kawamoto T, Hori M, Shimazaki J, Yoshimi F, Fukao K. Expression and prognostic roles of beta-catenin in hepatocellular carcinoma: correlation with tumor progression and postoperative survival. Clin Cancer Res 2002; 8: 450-456 [PMID: 11839663]
30. Nhieu JT, Renard CA, Wei Y, Cherqui D, Zafrani ES, Buendia MA. Nuclear accumulation of mutated beta-catenin in hepatocellular carcinoma is associated with increased cell proliferation. Am J Pathol 1999; 155: 703-710 [PMID: 10487827]
31. Wang B, Xunsun JY, Yang D, Yang LL, Kong DX, Meng XW. The effect of cell cycle and expression of cyclin B1 and cyclin C protein in hepatocellular carcinoma cell line HepG2 and SMMC-7721 after of silencing β-catenin gene. Hepatogastroenterology 2012; 59: 515-518 [PMID: 22024040 DOI: 10.5754/hge11534]
32. Liu G, Jiang S, Wang C, Jiang W, Liu Z, Liu C, Saiyin H, Yang X, Shen S, Jiang D, Zhou P, Han D, Hu X, Yi Q, Yu L. Zinc fnger transcription factor 191, directly binding to β-catenin promoter, promotes cell proliferation of hepatocellular carcinoma. Hepatology 2012; 55: 1830-1839 [PMID: 22213192 DOI: 10.1002/hep.25564]
33. Taniguchi K, Roberts LR, Aderca IN, Dong X, Qian C, Murphy LM, Nagorney DM, Burgart LJ, Roche PC, Smith DI, Ross JA, Liu W. Mutational spectrum of beta-catenin, AXIN1, and AXIN2 in hepatocellular carcinomas and hepatoblastomas. Oncogene 2002; 21: 4863-4871 [PMID: 12101426 DOI: 10.1038/sj.onc.1205591]
34. Bengochea A, de Souza MM, Lefrançois L, Le Roux E, Galy O, Chemin I, Kim M, Wands JR, Trepo C, Hainaut P, Scoazec JY, Vitvitski L, Merle P. Common dysregulation of Wnt/Frizzled receptor elements in human hepatocellular carcinoma. Br J Cancer 2008; 99: 143-150 [PMID: 18577996 DOI: 10.1038/sj.bjc.6604422]
35. Qu B, Liu BR, DU YJ, Chen J, Cheng YQ, Xu W, Wang XH. Wnt/β-catenin signaling pathway may regulate the expression of angiogenic growth factors in hepatocellular carcinoma. Oncol Lett 2014; 7: 1175-1178 [PMID: 24944688 DOI: 10.3892/ol.2014.1828]
36. Ji J, Wang XW. Clinical implications of cancer stem cell biology in hepatocellular carcinoma. Semin Oncol 2012; 39: 461-472 [PMID: 22846863 DOI: 10.1053/j.seminoncol.2012.05.011]
37. Takahashi-Yanaga F, Kahn M. Targeting Wnt signaling: can we safely eradicate cancer stem cells? Clin Cancer Res 2010; 16: 3153-3162 [PMID: 20530697 DOI: 10.1158/1078-0432. CCR-09-2943]
38. Song W, Li H, Tao K, Li R, Song Z, Zhao Q, Zhang F, Dou K. Expression and clinical signifcance of the stem cell marker CD133 in hepatocellular carcinoma. Int J Clin Pract 2008; 62: 1212-1218 [PMID: 18479363 DOI: 10.1111/j.1742-1241.2008.01777.x]
39. Yang ZF, Ho DW, Ng MN, Lau CK, Yu WC, Ngai P, Chu PW, Lam CT, Poon RT, Fan ST. Signifcance of CD90+ cancer stem cells in human liver cancer. Cancer Cell 2008; 13: 153-166 [PMID: 18242515 DOI: 10.1016/j.ccr.2008.01.013]
40. Hou Y, Zou Q, Ge R, Shen F, Wang Y. The critical role of CD133(+)CD44(+/high) tumor cells in hematogenous metastasis of liver cancers. Cell Res 2012; 22: 259-272 [PMID: 21862973 DOI: 10.1038/cr.2011.139]
41. Yamashita T, Ji J, Budhu A, Forgues M, Yang W, Wang HY, Jia H, Ye Q, Qin LX, Wauthier E, Reid LM, Minato H, Honda M, Kaneko S, Tang Z Y, Wang XW. EpCAM-positive hepatocellular carcinoma cells are tumor-initiating cells with stem/progenitor cell features. Gastroenterology 2009; 136: 1012-1024 [PMID: 19150350 DOI: 10.1053/j.gastro.2008.12.004]
42. Quan MF, Xiao LH, Liu ZH, Guo H, Ren KQ, Liu F, Cao JG, Deng XY. 8-bromo-7-methoxychrysin inhibits properties of liver cancer stem cells via downregulation of β-catenin. World J Gastroenterol 2013; 19: 7680-7695 [PMID: 24431896 DOI: 10.3748/wjg.v19.i43.7680]
43. Liu L, Cao Y, Chen C, Zhang X, McNabola A, Wilkie D, Wilhelm S, Lynch M, Carter C. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res 2006; 66: 11851-11858 [PMID: 17178882 DOI: 10.1158/0008-5472. CAN-06-1377]
44. Gedaly R, Galuppo R, Musgrave Y, Angulo P, Hundley J, Shah M, Daily MF, Chen C, Cohen DA, Spear BT, Evers BM. PKI-587 and sorafenib alone and in combination on inhibition of liver cancer stem cell proliferation. J Surg Res 2013; 185: 225-230 [PMID: 23769634 DOI: 10.1016/j.jss.2013.05.016]
45. Newell P, Toffanin S, Villanueva A, Chiang DY, Minguez B, Cabellos L, Savic R, Hoshida Y, Lim KH, Melgar-Lesmes P, Yea S, Peix J, Deniz K, Fiel MI, Thung S, Alsinet C, Tovar V, Mazzaferro V, Bruix J, Roayaie S, Schwartz M, Friedman SL, Llovet JM. Ras pathway activation in hepatocellular carcinoma and anti-tumoral effect of combined sorafenib and rapamycin in vivo. J Hepatol 2009; 51: 725-733 [PMID: 19665249 DOI: 10.1016/j.jhep.2009.03.028]
46. Calin GA, Croce CM. MicroRNA signatures in human cancers. Nat Rev Cancer 2006; 6: 857-866 [PMID: 17060945 DOI: 10.1038/nrc1997]
47. Chen XM. MicroRNA signatures in liver diseases. World J Gastroenterol 2009; 15: 1665-1672 [PMID: 19360909 DOI: 10.3748/wjg.15.1665]
48. Di Masi A, Viganotti M, Antoccia A, Magrelli A, Salvatore M, Azzalin G, Tosto F, Lorenzetti S, Maranghi F, Mantovani A, Macino G, Tanzarella C, Taruscio D. Characterization of HuH6, Hep3B, HepG2 and HLE liver cancer cell lines by WNT/β-catenin pathway, microRNA expression and protein expression profile. Cell Mol Biol (Noisy-le-grand) 2010; 56 Suppl: OL1299-OL1317 [PMID: 20937217]
49. Xu J, Zhu X, Wu L, Yang R, Yang Z, Wang Q, Wu F. MicroRNA-122 suppresses cell proliferation and induces cell apoptosis in hepatocellular carcinoma by directly targeting Wnt/β-catenin pathway. Liver Int 2012; 32: 752-760 [PMID: 22276989 DOI: 10.1111/j.1478-3231.2011.02750.x]
50. Augello C, Vaira V, Caruso L, Destro A, Maggioni M, Park YN, Montorsi M, Santambrogio R, Roncalli M, Bosari S. MicroRNA profiling of hepatocarcinogenesis identifies C19MC cluster as a novel prognostic biomarker in hepatocellular carcinoma. Liver Int 2012; 32: 772-782 [PMID: 22429613 DOI: 10.1111/j.1478-3231.2012.02795.x]
51. Ji J, Shi J, Budhu A, Yu Z, Forgues M, Roessler S, Ambs S, Chen Y, Meltzer PS, Croce CM, Qin LX, Man K, Lo CM, Lee J, Ng IO, Fan J, Tang Z Y, Sun HC, Wang XW. MicroRNA expression, survival, and response to interferon in liver cancer. N Engl J Med 2009; 361: 1437-1447 [PMID: 19812400 DOI: 10.1056/NEJMoa0901282]
52. Ji J, Yamashita T, Wang XW. Wnt/beta-catenin signaling activates microRNA-181 expression in hepatocellular carcinoma. Cell Biosci 2011; 1: 4 [PMID: 21711587 DOI: 10.1186/2045-3701-1-4]
53. Gedaly R, Angulo P, Hundley J, Daily MF, Chen C, Koch A, Evers BM. PI-103 and sorafenib inhibit hepatocellular carcinoma cell proliferation by blocking Ras/Raf/MAPK and PI3K/AKT/mTOR pathways. Anticancer Res 2010; 30: 4951-4958 [PMID: 21187475]
54. Lepourcelet M, Chen YN, France DS, Wang H, Crews P, Petersen F, Bruseo C, Wood AW, Shivdasani RA. Small-molecule antagonists of the oncogenic Tcf/beta-catenin protein complex. Cancer Cell 2004; 5: 91-102 [PMID: 14749129]
55. Sukhdeo K, Mani M, Zhang Y, Dutta J, Yasui H, Rooney MD, Carrasco DE, Zheng M, He H, Tai YT, Mitsiades C, Anderson KC, Carrasco DR. Targeting the beta-catenin/TCF transcriptional complex in the treatment of multiple myeloma. Proc Natl Acad Sci USA 2007; 104: 7516-7521 [PMID: 17452641 DOI: 10.1073/pnas.0610299104]
56. Minke KS, Staib P, Puetter A, Gehrke I, Gandhirajan RK, Schlösser A, Schmitt EK, Hallek M, Kreuzer KA. Small molecule inhibitors of WNT signaling effectively induce apoptosis in acute myeloid leukemia cells. Eur J Haematol 2009; 82: 165-175 [PMID: 19067737 DOI: 10.1111/j.1600-0609.2008.01188.x]
57. Gandhirajan RK, Staib PA, Minke K, Gehrke I, Plickert G, Schlösser A, Schmitt EK, Hallek M, Kreuzer KA. Small molecule inhibitors of Wnt/beta-catenin/lef-1 signaling induces apoptosis in chronic lymphocytic leukemia cells in vitro and in vivo. Neoplasia 2010; 12: 326-335 [PMID: 20360943 DOI: 10.1593/neo.91972]
58. Wei W, Chua MS, Grepper S, So S. Small molecule antagonists of Tcf4/beta-catenin complex inhibit the growth of HCC cells in vitro and in vivo. Int J Cancer 2010; 126: 2426-2436 [PMID: 19662654 DOI: 10.1002/ijc.24810]
59. Yamashita T, Budhu A, Forgues M, Wang XW. Activation of hepatic stem cell marker EpCAM by Wnt-beta-catenin signaling in hepatocellular carcinoma. Cancer Res 2007; 67: 10831-10839 [PMID: 18006828 DOI: 10.1158/0008-5472.CAN-07-0908]
60. Thorne CA, Hanson AJ, Schneider J, Tahinci E, Orton D, Cselenyi CS, Jernigan KK, Meyers KC, Hang BI, Waterson AG, Kim K, Melancon B, Ghidu VP, Sulikowski GA, LaFleur B, Salic A, Lee LA, Miller DM, Lee E. Small-molecule inhibition of Wnt signaling through activation of casein kinase 1α. Nat Chem Biol 2010; 6: 829-836 [PMID: 20890287 DOI: 10.1038/nchembio.453]
61. Huang SM, Mishina YM, Liu S, Cheung A, Stegmeier F, Michaud GA, Charlat O, Wiellette E, Zhang Y, Wiessner S, Hild M, Shi X, Wilson CJ, Mickanin C, Myer V, Fazal A, Tomlinson R, Serluca F, Shao W, Cheng H, Shultz M, Rau C, Schirle M, Schlegl J, Ghidelli S, Fawell S, Lu C, Curtis D, Kirschner MW, Lengauer C, Finan PM, Tallarico JA, Bouwmeester T, Porter JA, Bauer A, Cong F. Tankyrase inhibition stabilizes axin and antagonizes Wnt signalling. Nature 2009; 461: 614-620 [PMID: 19759537 DOI: 10.1038/nature08356]
62. Behrens J, Jerchow BA, Würtele M, Grimm J, Asbrand C, Wirtz R, Kühl M, Wedlich D, Birchmeier W. Functional interaction of an axin homolog, conductin, with beta-catenin, APC, and GSK3beta. Science 1998; 280: 596-599 [PMID: 9554852]
63. Kishida M, Koyama S, Kishida S, Matsubara K, Nakashima S, Higano K, Takada R, Takada S, Kikuchi A. Axin prevents Wnt-3a-induced accumulation of beta-catenin. Oncogene 1999; 18: 979-985 [PMID: 10023673 DOI: 10.1038/sj.onc.1202388]
64. Hart MJ, de los Santos R, Albert IN, Rubinfeld B, Polakis P. Downregulation of beta-catenin by human Axin and its association with the APC tumor suppressor, beta-catenin and GSK3 beta. Curr Biol 1998; 8: 573-581 [PMID: 9601641]
65. Gurney A, Axelrod F, Bond CJ, Cain J, Chartier C, Donigan L, Fischer M, Chaudhari A, Ji M, Kapoun AM, Lam A, Lazetic S, Ma S, Mitra S, Park IK, Pickell K, Sato A, Satyal S, Stroud M, Tran H, Yen WC, Lewicki J, Hoey T. Wnt pathway inhibition via the targeting of Frizzled receptors results in decreased growth and tumorigenicity of human tumors. Proc Natl Acad Sci USA 2012; 109: 11717-11722 [PMID: 22753465 DOI: 10.1073/pnas.1120068109]
66. Wei W, Chua MS, Grepper S, So SK. Soluble Frizzled-7 receptor inhibits Wnt signaling and sensitizes hepatocellular carcinoma cells towards doxorubicin. Mol Cancer 2011; 10: 16 [PMID: 21314951 DOI: 10.1186/1476-4598-10-16]
67. Nambotin SB, Lefrancois L, Sainsily X, Berthillon P, Kim M, Wands JR, Chevallier M, Jalinot P, Scoazec J Y, Trepo C, Zoulim F, Merle P. Pharmacological inhibition of Frizzled-7 displays anti-tumor properties in hepatocellular carcinoma. J Hepatol 2011; 54: 288-299 [PMID: 21055837 DOI: 10.1016/j.jhep.2010.06.033]
68. Khoo BY, Chua SL, Balaram P. Apoptotic effects of chrysin in human cancer cell lines. Int J Mol Sci 2010; 11: 2188-2199 [PMID: 20559509 DOI: 10.3390/ijms11052188]
69. Handeli S, Simon JA. A small-molecule inhibitor of Tcf/beta-catenin signaling down-regulates PPARgamma and PPARdelta activities. Mol Cancer Ther 2008; 7: 521-529 [PMID: 18347139 DOI: 10.1158/1535-7163.MCT-07-2063]
70. Kril LM, Vilchez V, Jiang J, Turcios L, Chen C, Sviripa VM, Zhang W, Liu C, Spear B, Watt DS, Gedaly R. N-Aryl benzenesulfonamide inhibitors of [3H]-thymidine incorporation and β-catenin signaling in human hepatocyte-derived Huh-7 carcinoma cells. Bioorg Med Chem Lett 2015; 25: 3897-3899 [PMID: 26243371 DOI: 10.1016/j.bmcl.2015.07.040]
71. Qin Y, Lu Y, Wang R, Li W, Qu X. SL1122-37, a novel derivative of sorafenib, has greater effects than sorafenib on the inhibition of human hepatocellular carcinoma (HCC) growth and prevention of angiogenesis. Biosci Trends 2013; 7: 237-244 [PMID: 24241174]
72. Tian XH, Hou WJ, Fang Y, Fan J, Tong H, Bai SL, Chen Q, Xu H, Li Y. XAV939, a tankyrase 1 inhibitior, promotes cell apoptosis in neuroblastoma cell lines by inhibiting Wnt/β-catenin signaling pathway. J Exp Clin Cancer Res 2013; 32: 100 [PMID: 24308762 DOI: 10.1186/1756-9966-32-100]
73. Waaler J, Machon O, Tumova L, Dinh H, Korinek V, Wilson SR, Paulsen JE, Pedersen NM, Eide TJ, Machonova O, Gradl D, Voronkov A, von Kries JP, Krauss S. A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice. Cancer Res 2012; 72: 2822-2832 [PMID: 22440753 DOI: 10.1158/0008-5472. CAN-11-3336]
74. Bao R, Christova T, Song S, Angers S, Yan X, Attisano L. Inhibition of tankyrases induces Axin stabilization and blocks Wnt signalling in breast cancer cells. PLoS One 2012; 7: e48670 [PMID: 23144924 DOI: 10.1371/journal.pone.0048670]
75. Busch AM, Johnson KC, Stan RV, Sanglikar A, Ahmed Y, Dmitrovsky E, Freemantle SJ. Evidence for tankyrases as antineo-plastic targets in lung cancer. BMC Cancer 2013; 13: 211 [PMID: 23621985 DOI: 10.1186/1471-2407-13-211]
76. Ma L, Wang X, Jia T, Wei W, Chua MS, So S. Tankyrase inhibitors attenuate WNT/β-catenin signaling and inhibit growth of hepatocellular carcinoma cells. Oncotarget 2015; 6: 25390-25401 [PMID: 26246473 DOI: 10.18632/oncotarget.4455]